Glynn Wilson - Jan 24, 2023 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Director
Signature
/s/ GLYNN WILSON
Stock symbol
CVKD
Transactions as of
Jan 24, 2023
Transactions value $
$0
Form type
4
Date filed
1/24/2023, 04:02 PM
Previous filing
Jan 19, 2023
Next filing
Jan 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVKD Common Stock Conversion of derivative security +50K 50K Jan 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVKD Convertible Promissory Note Conversion of derivative security -50K -100% 0 Jan 24, 2023 Common Stock 50K $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share.